New data shows that live-attenuated influenza vaccines (LAIV) increase cross-reactive T-cell responses among children, with the potential to provide cross-protective immunity among drifted and hereto-variant influenza strains.
Researchers report that pandemic influenza vaccines were 73 percent effective at preventing confirmed influenza infection, and 61 percent effective at preventing hospitalization.
Unlike other potential universal influenza vaccines this could be administered once.
Scientists report progress toward a vaccine that could protect against flu permanently with one injection or with an injection every five to 10 years.
The vaccine could potentially offer protection for up to 88 percent of known flu strains.
Researchers have discovered an immune antibody that can evolve to neutralize a wide array of influenza virus strains.
This type of vaccine would be effective against multiple subtypes of influenza eliminating the need to produce a new vaccine each year.